<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162860</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00562</org_study_id>
    <nct_id>NCT04162860</nct_id>
  </id_info>
  <brief_title>Preemptive Endoluminal Negative Pressure in Minimally Invasive Transthoracic Esophagectomy</brief_title>
  <official_title>Preemptive Endoluminal Negative Pressure Therapy at the Anastomotic Site in Minimally Invasive Transthoracic Esophagectomy - An International Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the preSponge randomized controlled trial (RCT) will be to assess&#xD;
      the potential protective effects of preemptive endoscopic negative pressure therapy (ENP) on&#xD;
      postoperative morbidity in high-risk patients undergoing total minimally invasive&#xD;
      transthoracic esophagectomy with gastric pull-up reconstruction and high intrathoracic&#xD;
      anastomosis (thoracoscopic and laparoscopic Ivor Lewis esophagectomy).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of hospital stay until &quot;fit-for-discharge&quot; criteria are reached</measure>
    <time_frame>90-days postoperatively</time_frame>
    <description>The patients' oral/enteral nutritional requirements are met by oral intake of at least liquids with optional supplementary nutrition via jejunal feeding tube.&#xD;
The patient should have passed flatus.&#xD;
The patient does not require oxygen during mobilisation (short walk or climbing stairs) or at rest.&#xD;
Central venous catheters should be removed before discharge (unless present preoperatively).&#xD;
Adequate analgesia at rest and during mobilisation (pain score &lt;4 on a scale from 0 to 10) is achieved using both oral opioid and non-opioid analgesics.&#xD;
All vital signs should be normal unless abnormal preoperatively.&#xD;
Inflammatory parameters (white cell count, C-reactive protein) should be trending down and close to normal.&#xD;
There should be adequate support after discharge (assistance by family, ambulatory nursing, or rehabilitation facility).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Complications</measure>
    <time_frame>90-days postoperatively</time_frame>
    <description>Assessment of postoperative complications according to Clavien-Dindo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Complications</measure>
    <time_frame>90-days postoperatively</time_frame>
    <description>Hospital readmissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Complications</measure>
    <time_frame>90-days postoperatively</time_frame>
    <description>Anastomotic stricture</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Surgery--Complications</condition>
  <condition>Leak, Anastomotic</condition>
  <arm_group>
    <arm_group_label>minimally invasive esophagectomy with preemptive ENP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo a standard total minimally invasive transthoracic Ivor Lewis esophagectomy with preemptive ENP. After completion of the esophago-gastric anastomosis, an Eso-SPONGE® system will be inserted via an intraoperative gastroscopy. ENP will be carried out upon completion of the esophago-gastrostomy, but no later than 12 hours after the surgical intervention. Postoperatively, secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg. ENP will remain for 4 days and will be monitored with clinical parameters.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard minimally invasive esophagectomy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the control group will undergo a standard minimally invasive transthoracic Ivor Lewis esophagectomy without preemptive ENP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eso-SPONGE® device</intervention_name>
    <description>Preemptive ENP therapy will be carried out with either an Eso-SPONGE® device system (Eso-SPONGE®, B. Braun Melsungen AG, Melsungen, Germany). Eso-SPONGE® consists of an open-pored polyurethane foam fitted to a gastric tube. Secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg.</description>
    <arm_group_label>minimally invasive esophagectomy with preemptive ENP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        We will include adult patients (≥18 years of age) with resectable esophageal cancer&#xD;
        (adenocarcinoma or squamous cell carcinoma) with high risk for anastomotic leakage (AL) who&#xD;
        provided informed consent and are scheduled for minimally invasive transthoracic Ivor Lewis&#xD;
        esophagectomy. Robotic-assisted procedures will also be included.&#xD;
&#xD;
        Patients considered at high risk for AL must have at least one of the following risk&#xD;
        factors:&#xD;
&#xD;
          -  American Society of Anesthesiologists Classification (ASA) score &gt;2&#xD;
&#xD;
          -  Diabetes (insulin dependent or HbA1c ≥ 6.5%)&#xD;
&#xD;
          -  Chronic pulmonary disease (first second of forced expiration (FEV1)/Forced volume&#xD;
             vital capacity (FVC) ratio ≤ 70%)&#xD;
&#xD;
          -  Heart failure (left ventricular ejection fraction (LVEF) &lt;55%)&#xD;
&#xD;
          -  Preexisting cardiac arrhythmia (pacemaker or paroxysmal supraventricular&#xD;
             tachyarrhythmia)&#xD;
&#xD;
          -  Chronic kidney disease stage 4-5 (glomerular filtration rate (GFR) &lt; 30ml/min/1.73 m2)&#xD;
&#xD;
          -  Chronic liver disease with treated portal hypertension (porto-caval pressure gradient&#xD;
             ≥5-≤10mmHg, including patients with transjugular intrahepatic portosystemic shunt&#xD;
             (TIPS))&#xD;
&#xD;
          -  Previous radiotherapy or chemo-radiation ≥50Gray (Gy) (salvage esophagectomy)&#xD;
&#xD;
        Alternatively, patients must have at least two of the following risk factors:&#xD;
&#xD;
          -  Arteriosclerosis score 2 according to van Rossum et al.13 (aorta and coeliac axis)&#xD;
&#xD;
          -  Malnutrition (Body mass index (BMI) ≤ 18.5kg/m2)&#xD;
&#xD;
          -  Obesity (BMI ≥ 35kg/m2)&#xD;
&#xD;
          -  Heart failure with preserved ejection fraction (LVEF &gt;55%)&#xD;
&#xD;
          -  Active or former smoking&#xD;
&#xD;
          -  Age &gt; 65 years&#xD;
&#xD;
          -  World health Organisation (WHO)/Zubrodt score &gt; 1&#xD;
&#xD;
          -  chronic kidney disease stage 2-3 (GFR 30-89 ml/min/1.73 m2)&#xD;
&#xD;
          -  chronic liver disease without portal hypertension (porto-caval pressure gradient&#xD;
             ≤5mmHg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, or dementia.&#xD;
&#xD;
          -  Patients younger than 18 years&#xD;
&#xD;
          -  Patients undergoing esophagectomy for benign disease or for malignancy other than&#xD;
             adenocarcinoma or squamous cell carcinoma&#xD;
&#xD;
          -  Patients scheduled for other technical variants of esophagectomy, such as open,&#xD;
             hybrid, or transhiatal procedures (intraoperative conversions to open access surgery&#xD;
             will not be excluded)&#xD;
&#xD;
          -  Chronic liver disease with portal hypertension (porto-caval pressure gradient &gt;10mmHg)&#xD;
&#xD;
          -  Distant organ metastasis (cM+)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Gutschow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian A. Gutschow, MD</last_name>
    <phone>+41442559723</phone>
    <email>christian.gutschow@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian A. Gutschow, MD</last_name>
      <phone>+41 44 255 9723</phone>
      <email>christian.gutschow@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Christian Gutschow</investigator_full_name>
    <investigator_title>Professor, Head of upper gastrointestinal unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastomotic Leak</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

